Simplify Asset Management Inc. Has $435,000 Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Simplify Asset Management Inc. decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 34.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 9,397 shares of the company’s stock after selling 4,949 shares during the period. Simplify Asset Management Inc.’s holdings in LivaNova were worth $435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nordea Investment Management AB boosted its holdings in LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after purchasing an additional 12,470 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of LivaNova in the fourth quarter worth about $1,954,000. KBC Group NV boosted its stake in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after acquiring an additional 56,580 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after acquiring an additional 899 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of LivaNova by 17.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after acquiring an additional 93,311 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Stock Performance

NASDAQ LIVN opened at $39.48 on Friday. The company’s fifty day moving average is $45.31 and its two-hundred day moving average is $48.74. LivaNova PLC has a 52-week low of $36.85 and a 52-week high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 94.00 and a beta of 1.10.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.